Navigation Links
UTSW molecular biologist Olson wins March of Dimes developmental biology prize
Date:3/8/2013

DALLAS March 8, 2013 Dr. Eric Olson, chairman of molecular biology at UT Southwestern Medical Center, is the 2013 recipient of the March of Dimes Prize in Developmental Biology for identifying key genetic pathways in the formation of the heart and other muscles.

His work is credited with forging new insights into heart development and regeneration that could lead to novel treatments for heart disease and muscle dysfunction. Several drugs based on his research are currently under study.

Dr. Joe Leigh Simpson, senior vice president for research and global programs for the March of Dimes, said about 1 percent of newborns have heart abnormalities that occur during development.

"Dr. Olson's work has portrayed a detailed genetic model for heart development that provides a framework for how these genes function in normal and abnormal heart development. His work will surely lead to new ways to treat and prevent cardiac defects in infants as well as in adults," Dr. Simpson said.

Dr. Daniel K. Podolsky, president of UT Southwestern, said, "Dr. Olson's studies have led to profound insights into cardiac development and advanced our understanding of the basic mechanisms underlying altered cardiovascular function in disease. His work represents the very best in our faculty's efforts to pursue discoveries that can ultimately lead to better prevention and treatment of serious heart disease."

Dr. Olson joined the UTSW faculty in 1995 as chair of the then-newly formed Department of Molecular Biology. Dr. Olson, who earned his doctorate in biochemistry at Wake Forest University's Bowman Gray School of Medicine in 1981, was recruited from The University of Texas MD Anderson Cancer Center in Houston.

At UT Southwestern, Dr. Olson also directs the Nancy B. and Jake L. Hamon Center for Basic Research in Cancer. "I have been especially fortunate to work with an amazing group of colleagues at UT Southwestern, who made this award possible," Dr. Olson said. "Given that congenital heart disease is the most common human birth defect, I am also grateful that our work on heart development and disease was recognized on the 75th anniversary of the March of Dimes."

An elected member of the National Academy of Sciences, the Institute of Medicine, and the American Academy of Arts and Sciences, Dr. Olson has garnered numerous awards and honors, including the 2012 Passano Award and the Institut de France's prestigious Lefoulon-Delalande Foundation Grand Prize for Science from the French Academy of Sciences in 2009. He also has won the Pollin Prize for Pediatric Research, the Pasarow Award in Cardiovascular Medicine, the Outstanding Investigator Award from the International Society for Heart Research, and an inaugural Distinguished Scientist Award from the American Heart Association. He was awarded the AHA's National Research Achievement Award for work that the organization described as having "redrawn battle lines in the fight against heart disease."

Dr. Olson will be recognized at a May 6 dinner in Washington, D.C.


'/>"/>

Contact: Deborah Wormser
deborah.wormser@utsouthwestern.edu
214-648-3404
UT Southwestern Medical Center
Source:Eurekalert  

Related biology news :

1. Researchers find molecular switch turning on self-renewal of liver damage
2. Denmark joins the Nordic EMBL Partnership for Molecular Medicine
3. Antibacterial proteins molecular workings revealed
4. Scientists identify molecular system that could help develop treatments for Alzheimers disease
5. Molecular basis identified for tissue specific immune regulation in the eye and kidney
6. Explosive breakthrough in research on molecular recognition
7. Mainz scientists confirm original tetrahedral model of the molecular structure of water
8. FASEB SRC announces: Molecular Mechanisms & Physiological Consequences of Protein Aggregation
9. FASEB SRC announces conference registration open for: Ciliate Molecular Biology
10. Elsevier launches new open access journal: Molecular Metabolism
11. Virginia Tech computer scientists develop new way to study molecular networks
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
UTSW molecular biologist Olson wins March of Dimes developmental biology prize
(Date:3/31/2016)... R.I. , March 31, 2016  Genomics firm ... of founding CEO, Barrett Bready , M.D., who ... members of the original technical leadership team, including Chief ... President of Product Development, Steve Nurnberg and Vice President ... returned to the company. Dr. Bready served ...
(Date:3/23/2016)... March 23, 2016 ... Sicherheit Gesichts- und Stimmerkennung mit Passwörtern ... (NASDAQ: MESG ), ein führender Anbieter ... Unternehmen mit SpeechPro zusammenarbeitet, um erstmals dessen ... wird die Möglichkeit angeboten, im Rahmen mobiler ...
(Date:3/22/2016)... Ontario , PROVO and ... Newborn Screening Ontario (NSO), which operates the ... for molecular testing, and Tute Genomics and UNIConnect, ... management technology respectively, today announced the launch of a ... next-generation sequencing (NGS) testing panel. NSO ...
Breaking Biology News(10 mins):
(Date:6/24/2016)... ... June 24, 2016 , ... While the majority of commercial spectrophotometers and fluorometers ... the 6000i models are higher end machines that use the more unconventional z-dimension of ... beam from the bottom of the cuvette holder. , FireflySci has developed several ...
(Date:6/23/2016)... 2016 /PRNewswire/ - FACIT has announced the creation ... biotechnology company, Propellon Therapeutics Inc. ("Propellon" or "the ... a portfolio of first-in-class WDR5 inhibitors for the ... WDR5 represent an exciting class of therapies, possessing ... for cancer patients. Substantial advances have been achieved ...
(Date:6/23/2016)... 2016  The Biodesign Challenge (BDC), a university competition ... harness living systems and biotechnology, announced its winning teams ... New York City . The ... projects at MoMA,s Celeste Bartos Theater during the daylong ... senior curator of architecture and design, and Suzanne ...
(Date:6/23/2016)... Apellis Pharmaceuticals, Inc. today announced positive ... its complement C3 inhibitor, APL-2. The trials were ... studies designed to assess the safety, tolerability, pharmacokinetics ... healthy adult volunteers. Forty subjects were ... dose (ranging from 45 to 1,440mg) or repeated ...
Breaking Biology Technology: